Cite

HARVARD Citation

    Rizvi, A. et al. (2022). Safety and benefit of incretin-based therapies in patients with type 2 diabetes: learnings and reflections. Expert opinion on drug safety. 21 (3), pp. 291-293. [Online]. 
  
Back to record